



## Heterogeneity of Neuroendocrine Tumors: Impact on Biology and Response to Treatments

Guest Editors:

**Dr. Louis de Mestier**

Beaujon Hospital, Université de Paris, Paris, France

**Prof. Jérôme Cros**

Beaujon Hospital, Université de Paris, France


Deadline for manuscript submissions:  
**closed (31 August 2022)**

### Message from the Guest Editors

Recent advances in the understanding of NEN biology have resulted in a rising number of available treatments, including surgery, somatostatin analogs, chemotherapy, targeted therapies, liver-directed therapies, and peptide receptor radionuclide therapy. However, most of these treatments are used based on a low level of evidence, and comparisons between them have been scarce. In particular, the impact of the heterogeneity of NEN on treatment efficacy has been poorly explored. Because factors predictive of treatment efficacy are lacking, therapeutic decision-making is essentially influenced by prognostic factors.

This Special Issue aims to gather cutting-edge research on the characterization and therapeutic advances in NEN, with a focus on the impact of their heterogeneity on tumor biology and treatment efficacy. Original research and review articles should present new data from basic or clinical research and/or provide an innovative and critical appraisal of previous research. Papers exploring novel clinical or molecular biomarkers impacting prognosis and treatment efficacy are particularly welcome.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Samuel C. Mok

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

## Contact Us

---

Cancers Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
[X@Cancers\\_MDPI](https://twitter.com/Cancers_MDPI)